Cargando…
Combination of atorvastatin/coenzyme Q10 as adjunctive treatment in congestive heart failure: A double-blind randomized placebo-controlled clinical trial
BACKGROUND: Heart failure is one of the leading causes of mortality, is a final common pathway of several cardiovascular diseases, and its treatment is a major concern in the science of cardiology. The aim of the present study was to compare the effect of addition of the coenzyme Q10 (CoQ10)/atorvas...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063520/ https://www.ncbi.nlm.nih.gov/pubmed/24963306 |
_version_ | 1782321804581273600 |
---|---|
author | Pourmoghaddas, Masoud Rabbani, Majid Shahabi, Javad Garakyaraghi, Mohammad Khanjani, Reza Hedayat, Pegah |
author_facet | Pourmoghaddas, Masoud Rabbani, Majid Shahabi, Javad Garakyaraghi, Mohammad Khanjani, Reza Hedayat, Pegah |
author_sort | Pourmoghaddas, Masoud |
collection | PubMed |
description | BACKGROUND: Heart failure is one of the leading causes of mortality, is a final common pathway of several cardiovascular diseases, and its treatment is a major concern in the science of cardiology. The aim of the present study was to compare the effect of addition of the coenzyme Q10 (CoQ10)/atorvastatin combination to standard congestive heart failure (CHF) treatment versus addition of atorvastatin alone on CHF outcomes. METHODS: This study was a double-blind, randomized placebo-controlled trial. In the present study, 62 eligible patients were enrolled and randomized into 2 groups. In the intervention group patients received 10 mg atorvastatin daily plus 100 mg CoQ10 pearl supplement twice daily, and in the placebo group patients received 10 mg atorvastatin daily and the placebo of CoQ10 pearl for 4 months. For all patients echocardiography was performed and blood sample was obtained for determination of N-terminal B-type natriuretic peptide, total cholesterol, low density lipoprotein, erythrocyte sedimentation rate, and C-reactive protein levels. Echocardiography and laboratory test were repeated after 4 months. The New York Heart Association Function Class (NYHA FC) was also determined for each patient before and after the study period. RESULTS: Data analyses showed that ejection fraction (EF) and NYHA FC changes differ significantly between intervention and placebo group (P = 0.006 and P = 0.002, respectively). Changes in other parameters did not differ significantly between study groups. CONCLUSION: We deduce that combination of atorvastatin and CoQ10, as an adjunctive treatment of CHF, increase EF and improve NYHA FC in comparison with use of atorvastatin alone. |
format | Online Article Text |
id | pubmed-4063520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-40635202014-06-24 Combination of atorvastatin/coenzyme Q10 as adjunctive treatment in congestive heart failure: A double-blind randomized placebo-controlled clinical trial Pourmoghaddas, Masoud Rabbani, Majid Shahabi, Javad Garakyaraghi, Mohammad Khanjani, Reza Hedayat, Pegah ARYA Atheroscler Original Article BACKGROUND: Heart failure is one of the leading causes of mortality, is a final common pathway of several cardiovascular diseases, and its treatment is a major concern in the science of cardiology. The aim of the present study was to compare the effect of addition of the coenzyme Q10 (CoQ10)/atorvastatin combination to standard congestive heart failure (CHF) treatment versus addition of atorvastatin alone on CHF outcomes. METHODS: This study was a double-blind, randomized placebo-controlled trial. In the present study, 62 eligible patients were enrolled and randomized into 2 groups. In the intervention group patients received 10 mg atorvastatin daily plus 100 mg CoQ10 pearl supplement twice daily, and in the placebo group patients received 10 mg atorvastatin daily and the placebo of CoQ10 pearl for 4 months. For all patients echocardiography was performed and blood sample was obtained for determination of N-terminal B-type natriuretic peptide, total cholesterol, low density lipoprotein, erythrocyte sedimentation rate, and C-reactive protein levels. Echocardiography and laboratory test were repeated after 4 months. The New York Heart Association Function Class (NYHA FC) was also determined for each patient before and after the study period. RESULTS: Data analyses showed that ejection fraction (EF) and NYHA FC changes differ significantly between intervention and placebo group (P = 0.006 and P = 0.002, respectively). Changes in other parameters did not differ significantly between study groups. CONCLUSION: We deduce that combination of atorvastatin and CoQ10, as an adjunctive treatment of CHF, increase EF and improve NYHA FC in comparison with use of atorvastatin alone. Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences 2014-01 /pmc/articles/PMC4063520/ /pubmed/24963306 Text en © 2014 Isfahan Cardiovascular Research Center & Isfahan University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly. |
spellingShingle | Original Article Pourmoghaddas, Masoud Rabbani, Majid Shahabi, Javad Garakyaraghi, Mohammad Khanjani, Reza Hedayat, Pegah Combination of atorvastatin/coenzyme Q10 as adjunctive treatment in congestive heart failure: A double-blind randomized placebo-controlled clinical trial |
title | Combination of atorvastatin/coenzyme Q10 as adjunctive treatment in congestive heart failure: A double-blind randomized
placebo-controlled clinical trial |
title_full | Combination of atorvastatin/coenzyme Q10 as adjunctive treatment in congestive heart failure: A double-blind randomized
placebo-controlled clinical trial |
title_fullStr | Combination of atorvastatin/coenzyme Q10 as adjunctive treatment in congestive heart failure: A double-blind randomized
placebo-controlled clinical trial |
title_full_unstemmed | Combination of atorvastatin/coenzyme Q10 as adjunctive treatment in congestive heart failure: A double-blind randomized
placebo-controlled clinical trial |
title_short | Combination of atorvastatin/coenzyme Q10 as adjunctive treatment in congestive heart failure: A double-blind randomized
placebo-controlled clinical trial |
title_sort | combination of atorvastatin/coenzyme q10 as adjunctive treatment in congestive heart failure: a double-blind randomized
placebo-controlled clinical trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063520/ https://www.ncbi.nlm.nih.gov/pubmed/24963306 |
work_keys_str_mv | AT pourmoghaddasmasoud combinationofatorvastatincoenzymeq10asadjunctivetreatmentincongestiveheartfailureadoubleblindrandomizedplacebocontrolledclinicaltrial AT rabbanimajid combinationofatorvastatincoenzymeq10asadjunctivetreatmentincongestiveheartfailureadoubleblindrandomizedplacebocontrolledclinicaltrial AT shahabijavad combinationofatorvastatincoenzymeq10asadjunctivetreatmentincongestiveheartfailureadoubleblindrandomizedplacebocontrolledclinicaltrial AT garakyaraghimohammad combinationofatorvastatincoenzymeq10asadjunctivetreatmentincongestiveheartfailureadoubleblindrandomizedplacebocontrolledclinicaltrial AT khanjanireza combinationofatorvastatincoenzymeq10asadjunctivetreatmentincongestiveheartfailureadoubleblindrandomizedplacebocontrolledclinicaltrial AT hedayatpegah combinationofatorvastatincoenzymeq10asadjunctivetreatmentincongestiveheartfailureadoubleblindrandomizedplacebocontrolledclinicaltrial |